Aquestive Therapeutics, Inc.

Equities

AQST

US03843E1047

Market Closed - Nasdaq Other stock markets 04:00:00 2025-07-15 pm EDT			5-day change	1st Jan Change
4.020 ^USD	-0.25%		+9.24%	+12.92%

09:24am	Sector Update: Health Care Stocks Mixed Premarket Tuesday	MT
07:33am	Aquestive Therapeutics Says Canadian Regulator Has Granted Meeting to Discuss Anaphylm Approval	MT

Aquestive Therapeutics, Inc., Q1 2025 Earnings Call, May 13, 2025

Published on 05/13/2025 at 07:00, updated on 07/05/2025 at 14:46

Presentation Operator Message
Operator (Operator)

Good day and thank you for standing by. Welcome to the Aquestive Therapeutics First Quarter 2025 Earnings Conference Call. [Operator Instructions]

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Aquestive Therapeutics, Inc.

Sector Update: Health Care Stocks Mixed Premarket Tuesday	09:24am	MT
Aquestive Therapeutics Says Canadian Regulator Has Granted Meeting to Discuss Anaphylm Approval	07:33am	MT
Aquestive Therapeutics, Inc., Q1 2025 Earnings Call, May 13, 2025	Jul. 05
Aquestive Gets FDA Acceptance of New Drug Application for Severe Allergic Reaction Treatment	Jun. 16	MT
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm for the Treatment of Severe Allergic Reactions	Jun. 16	CI
Aquestive Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 12	CI
Aquestive Therapeutics, Inc. Revises Earnings Guidance for Full Year 2025	May. 12	CI
Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm? (epinephrine) Sublingual Film	Apr. 01	CI
Sector Update: Health Care Stocks Flat to Lower Premarket Thursday	Mar. 06	MT
Aquestive Therapeutics, Inc., Q4 2024 Earnings Call, Mar 06, 2025	Mar. 06
Aquestive Therapeutics Q4 Net Loss Widens, Revenue Falls; 2025 Revenue Outlook Issued	Mar. 06	MT
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update	Mar. 05	RE
Aquestive Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	Mar. 05	CI
Aquestive Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	Mar. 05	CI
Aquestive Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2025	Mar. 05	CI
Aquestive Therapeutics, Inc. to Present New Findings on Anaphylm? (Epinephrine Sublingual Film) At the 2025 AAAAI Annual Meeting	Feb. 12	CI
Aquestive Therapeutics, Inc.(NasdaqGM:AQST) added to NASDAQ Biotechnology Index	Dec. 22	CI
Sector Update: Health Care Stocks Lower Thursday Afternoon	Dec. 19	MT
Aquestive Therapeutics Says FDA Grants Orphan Drug Exclusivity for Libervant Buccal Film to Treat Seizure Clusters	Dec. 19	MT
Aquestive Therapeutics, Inc. Receives U.S. FDA Orphan Drug Exclusivity for Libervant® Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five	Dec. 19	CI
Cantor Fitzgerald Initiates Aquestive Therapeutics at Overweight With $17 Price Target	Dec. 17	MT
Aquestive Therapeutics Receives FDA 'Positive Feedback' for Anaphylm Sublingual Film	Dec. 02	MT
Aquestive Therapeutics, Inc. Announces Board and Committee Changes	Nov. 07	CI
Aquestive Therapeutics, Inc. Provides Earnings Guidance for 2024	Nov. 05	CI
Aquestive Therapeutics, Inc., Q3 2024 Earnings Call, Nov 05, 2024	Nov. 05